Of note, metabolic differences have also been reported between LSCs from de novo and those from R/R AML patients, with the former preferentially utilizing BCL-2-dependent amino acid-driven OXPHOS and the latter also utilizing FAO-driven OXPHOS [2,14]. The gene discussed is BCL2; the disease is acute myeloid leukemia.